VFA
IOVA icon

Virtus Fund Advisers’s Iovance Biotherapeutics IOVA Stock Holding History

Virtus Fund Advisers’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$322K Buy
+40,259
New +$323K ﹤0.01% 441

Other funds holding IOVA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Virtus Fund Advisers's IOVA Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Iovance Biotherapeutics (IOVA) in Q4 2017: 40,259 shares worth $322K. The stake represents ﹤0.01% of the portfolio and ranks #441 among its holdings.

87 funds tracked by Wall St. Rank hold IOVA as of Q4 2017.

  • Virtus Fund Advisers held 40,259 shares of Iovance Biotherapeutics worth $322K as of Q4 2017.
  • Iovance Biotherapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Iovance Biotherapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #441 holding.
  • 87 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.